DOI: 10.36347/sjams.2018.v06i12.043

Pages: 4848-4855

To evaluate the effects of travoprost with Benzalkonium chloride(BAC) versus travoprost with Stabilized Oxy chloride complex(SOC) on ocular surface in case of primary open angle glaucoma (POAG). Our study involved 56 patients (112 eyes) who received antiglaucomatous treatment by instillation of one drop of travoprost (0.004%) with SOC (0.005%) group 1 (56 eyes of 28 patients) and travoprost with BAC (0.015%) group 2 (56 eyes of 28 patients) every 24 hours. Patients completed Ocular Surface Disease Index questionnaire, underwent evaluation by Schirmer test, tear breakup time, corneal and conjunctival fluorescein and lissamine green staining. In group 1-at the end of 6 months, 14.28% eyes were abnormal in schirmer test, 23.21% in TBUT, 28.57% had abnormal scoring in both staining, mild to moderate OSDI score was seen in 53.57% and severe OSDI score in 14.28%. In group 2- 19.64% eyes were abnormal in schirmer test, 55.35% in TBUT, 39.2% had abnormal scoring in both staining, mild to moderate OSDI score was seen in 57.14% and none of the patients had severe OSDI score. High prevalence of ocular surface diseases was noted in patients using travoprost with Benzalkonium chloride as compared with travoprost with Stabilized Oxy chloride complex. Ocular surface disease must be kept in mind in symptomatic patients as it is likely to affect drug compliance.